期刊
JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY
卷 17, 期 3, 页码 625-634出版社
SAGE PUBLICATIONS INC
DOI: 10.1177/19322968221137335
关键词
diabetes; wearable technology; continuous subcutaneous insulin infusion; insulin pump; hybrid closed-loop; inpatient
This article provides a review and summary of the JBDS-IP guidelines on diabetes technology use in hospitalized patients. It focuses on the use of insulin pumps and hybrid closed-loop systems, highlighting the need for specialist guidance and knowledge of the devices before continuing their use.
This article is the second of a two-part series providing a scoping review and summary of the Joint British Diabetes Societies for Inpatient Care (JBDS-IP) guidelines on the use of diabetes technology in people with diabetes admitted to hospital. The first part reviewed the use of continuous glucose monitoring (CGM) in hospital. In this article, we focus on the use of continuous subcutaneous insulin infusion (CSII; insulin pumps) and hybrid closed-loop systems in hospital. JBDS-IP advocates enabling people who can self-manage and are willing and capable of using CSII to continue doing so as they would do out of hospital. CSII should be discontinued if the individual is critically ill or hemodynamically unstable. For individuals on hybrid closed-loop systems, the system should be discontinued from auto-mode, and may be used individually (as CGM only or CSII only, if criteria are met). Continuing in closed-loop mode may only be done so under specialist guidance from the Diabetes Team, where the diabetes teams are comfortable and knowledgeable about the specific devices used. Health care organizations need to have clear local policies and guidance to support individuals using these wearable technologies, and ensure the relevant workforce is capable and skilled enough to ensure their safe use within the hospital setting.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据